KalVista Pharmaceuticals Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Palleiko Benjamin L unloaded Company’s shares for reported $0.1 million on Jun 09 ’25. In the deal valued at $14.50 per share,7,169 shares were sold. As a result of this transaction, Palleiko Benjamin L now holds 315,074 shares worth roughly $3.76 million.
Then, Audhya Paul K. sold 2,146 shares, generating $24,272 in total proceeds. Upon selling the shares at $11.31, the CHIEF MEDICAL OFFICER now owns 113,026 shares.
Before that, Yea Christopher sold 1,926 shares. KalVista Pharmaceuticals Inc shares valued at $21,782 were divested by the CHIEF DEVELOPMENT OFFICER at a price of $11.31 per share. As a result of the transaction, Yea Christopher now holds 98,189 shares, worth roughly $1.17 million.
JMP Securities initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Mkt outperform in a research note published on January 31, 2025; the price target was $19. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. BofA Securities began covering KALV with “Buy” recommendation on December 18, 2024. H.C. Wainwright started covering the stock on June 15, 2020. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Monday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock fall -1.81%% to $11.93. Over the last five days, the stock has lost -7.95%. KalVista Pharmaceuticals Inc shares have risen nearly 4.93% since the year began. Nevertheless, the stocks have risen 40.85% over the past one year. While a 52-week high of $15.50 was reached on 06/10/25, a 52-week low of $7.30 was recorded on 01/13/25.
Levels Of Support And Resistance For KALV Stock
The 24-hour chart illustrates a support level at 11.69, which if violated will result in even more drops to 11.44. On the upside, there is a resistance level at 12.25. A further resistance level may holdings at 12.56.
The most recent change occurred on July 29, 2019 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
